T. Reed Stephens represents clients in the life sciences industry, including pharmaceutical and biotech manufacturers, wholesalers and individuals, as well as health care systems and non-health care related companies in other global industries such as the defense and financial services/banking sectors. He also represents clients in matters involving state and federal government law enforcement, voluntary disclosures and congressional investigations.
Reed advises clients on risk management concerns that involve mergers and acquisitions, public policy, intellectual property protection and an array of regulatory compliance matters in connection with product marketing, foreign bribery prohibitions and import/export controls.
Reed is a nationally recognized authority in the pharmaceutical fraud and abuse and corporate compliance area, speaking to the industry on a regular basis. Reed advises pharmaceutical manufacturer clients on government drug pricing counseling and voluntary disclosures in the areas of Medicaid Drug Rebate, Federal Supply Schedule/Department of Veteran Affairs, and the 340B program. He also represents hospital systems and managed care companies in a wide variety of internal and external government investigations issues. Reed has extensive experience litigating Anti-Kickback Statute and Stark Physician Self-Referral Law False Claims Act matters, including United States ex rel. Kunz v. Halifax, et al. qui tam litigation in the Middle District of Florida. He has negotiated corporate integrity agreements opposite the US Department of Health and Human Services Office of Counsel to the Inspector General (OIG).
During his more than seven-year tenure as a trial attorney with the Department of Justice Civil Division, he was lead or co-lead counsel in more than 60 investigations, the majority involving allegations of health care fraud perpetrated against various government agencies. Reed was lead counsel for the United States in the first successful cases against the pharmaceutical industry that involved Average Wholesale Price (AWP) reporting (US ex rel. Ven-A-Care v. et al.), Medicaid Drug Rebate price reporting (US ex rel. Foster v. Parke-Davis, US ex rel. Alcorn v. Schering-Plough) and Prescription Drug Marketing Act fraud (US ex rel. Gerstein v. TAP Pharmaceuticals). He was also lead counsel in significant non-health care government contract fraud matters involving the Department of Defense.
Reed clerked for the Honorable Clifford Scott Green of the US District Court for the Eastern District of Pennsylvania. While in law school, he served on the articles board of the Stanford Law Review.
Obtained summary judgment for defendants on non-intervened False Claims Act allegations involving more than $450 million in alleged damages for Anti-Kickback Statute, Stark law and Medicare lack of medical necessity violations in United States ex rel. Kunz v. Halifax Health, et al. (M.D. Florida 2014)
Represented a major pharmaceutical manufacturer in a joint US Senate and US House of Representatives Congressional investigation of pharmaceutical product price increases (2014)
Represented several health systems in the long-running Medicare short stay Kyphoplasty medical necessity False Claims Act qui tam, United States ex rel. Bates and Patrick v. [Under Seal], (W.D. New York)
Do not send any information or documents that you want to have treated as secret or confidential. Providing information to McDermott via email links on this website or other introductory email communications will not create an attorney-client relationship; will not preclude McDermott from representing any other person or firm in any matter; and will not obligate McDermott to keep confidential the information you provide. McDermott cannot enter into an attorney-client relationship with you until McDermott has determined that doing so will not create a conflict of interest and until you and McDermott have entered into a written agreement or engagement letter that sets forth the terms of our relationship.